Simufilam's Phase 3 Alzheimer's Trial Fails to Meet Endpoint Cassava Sciences (SAVA.US) Crashes Over 84%

Market IntelMonday, Nov 25, 2024 10:01 am ET

1min read

On Monday, Cassava Sciences (SAVA.US) stock plunged over 84% to $4.06 at the time of writing. The company said that the preliminary results of its 3rd phase ReThink-ALZ study of simufilam for mild to moderate Alzheimer's disease did not meet the pre-defined primary, secondary, and exploratory biomarker endpoints.

"The results are disappointing for patients with the disease and their families, as well as for physicians who have been looking for new treatment options," said Rick Barry, president and CEO of the company. "Given today's results, we have made the difficult decision to stop the Refocus-ALZ trial, which will provide a complete 52-week dataset as well as a significant portion of the 76-week dataset. We plan to report a detailed analysis of both studies in the future. We will also terminate the open-label extension study."

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.